Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferric carboxymaltose in chronic heart failure with iron deficiency
NCT00821717Phase 3Terminated
- Sponsor
- CSL Vifor
- Start
- Dec 2008
- Primary completion
- Oct 2009
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, single-blind trial in iron deficiency anemia (IDA) and chronic heart failure (CHF) comparing Ferric carboxymaltose with Placebo (2 arms). Primary endpoints: 6-Minute Walk Test distance at 24 weeks and New York Heart Association Functional Class at 24 weeks. Started Dec 2008; status: terminated.
02
Drugs
ferric carboxymaltose
03
Conditions
iron deficiency anemia (IDA)chronic heart failure (CHF)
Beyond the preview
Go deeper on NCT00821717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00821717.